home icon user icon
Welcome to International Network for Natural Sciences | INNS Pub.
Home My Account
Submit Manuscript
double_slash
breadcumb_bg

The prevalence of extended spectrum beta-lactamases (ESBLs) among Escherichia coli and Klebsiella species urinary isolates from Abia state university teaching hospital (ABSUTH) aba, Abia State Nigeria

Paper Details

Research Paper 01/07/2014
Views (319) Download (16)
current_issue_feature_image
publication_file

The prevalence of extended spectrum beta-lactamases (ESBLs) among Escherichia coli and Klebsiella species urinary isolates from Abia state university teaching hospital (ABSUTH) aba, Abia State Nigeria

I. L. Nwosu, E. S. Amadi, C. E. Nwanyanwu, C. I. Chikwendu, C. L. Madu
Int. J. Micro. Myco.2( 3), 20-28, July 2014.
Certificate: IJMM 2014 [Generate Certificate]
Key: Beta-lactamases (ESBLs)PrevalenceUrinary isolates

Abstract

The prevalence of extended spectrum β-lactamases among 246 clinical isolates from Abia State University teaching Hospital patients was investigated. The isolates were made up of 134 Escherichia coli and 112 Klebsiella species. Antimicrobial susceptibility of the isolates was determined by the disc diffusion method. ESBL phenotypes were determined by the double disc synergy method using ceftazidime, cefotaxime, ceftriaxone and co-amoxiclav. Out of the 246 isolates, 125 (50.8%) were ESBL producers, made up of 62(50.8%) E. coli and 63 (50.4%) Klebsiella isolates. Seventeen (54.8%) of the ESBL producing E. coli isolates were from in-patients while 45 (47.9%) were from out-patients. For the ESBL positive Klebsiella spp., 14 (45.2%) and 49 (52.1%) were from in-patients and out-patients respectively. ESBL producing isolates were also found to be more prevalent among the female patients (72.8%) than among the male patients (27.2%). The isolates also expressed high rates of resistance to other classes of antibiotics tested. However, Amikacin was found to have excellent performance against the urinary isolates tested and therefore is recommended for the treatment of infections caused by Escherichia coli and Klebsiella species. This study shows high prevalence of ESBL producing E. coli and Klebsiella isolates clinical samples of patients attending the Abia State University Teaching Hospital Aba, Abia State Nigeria.

VIEWS 26
Cover PDF

Akujobi CN, Ewuru CP. 2010. Detection of extended spectrum beta-lactamases in gram negative bacilli from clinical specimens in a teaching in South eastern Nigeria. Nigerian Medical Journal. 51,141-146.

Ali AM. 2009. Frequency of Extended Spectrum Beta Lactamase (ESBL) Producing Nosocomial Isolates In A Tertiary Care Hospital In Rawalpindi, A Journal of Army Medical Corps, 3, 0030-9648.

Al-Zarouni M, Senok A, Rashid F, Al-Jesmi SM, Panigrahi D. 2008. Prevalence and antimicrobial susceptibility pattern of extended-spectrum beta-lactamase-producing Enterobacteriaceae in the United Arab Emirates. Medical Principles and Practice, 17(1), 32-36.

Blomberg B, Jureen R, Manji KP. 2005. High rate of fatal pediatric septicemia caused by gram-negative bacteria with extended-spectrum beta-lactamases in Dares Salaam,Tanzania. Journal of Clinical Microbiology; 43,745-49.

Chaudhary U, Aggarwal R. 2004. Extended spectrum beta lactamases (ESBL) An emerging threat to clinical theraputics, Indian Journal of Medical Microbiology, 22 (2), 75-80.

CLSI. 2010. Clinical  and  Laboratory  Standards Institute. Performance Standards for Antimicrobial Susceptibility Testing, Twentieth Informational Supplement, CLSI Document M100-S20, Wayne, PA: Clinical and Laboratory Standards Institute.

Chowdhury MA, Yamanaka H, Miyoshi S, Aziz KM, Shinoda S. 1994. Ecology of Vibrio mimicus in aquatic environments, Applied and Environmental Microbiology, 55(8), 2073-2078

Denholm JT, Huysmans M, Spelman D. 2009. Community acquisition of ESBL-producing Escherichia coli: a growing concern, Medical Journal of Australia, 190(1), 45-46.

Gonzalez LS, Spencer JP. 1998. Aminoglycosides: a practical review, American Family Physician, 58(8), 1811-1820.

Harding G, Ronald R. 1994. The management of urinary infections: what have we learned in the past decade? International Journal of Antimicrobial Agents, 4, 83–88.

Haque R, Salam M. 2010. Detection of ESBL producing nosocomial gram negative bacteria from a tertiary care hospital in Bangladesh, Pakistan Journal of Medical Sciences, 26 (4), 887-891.

Heffernan H, Woodhouse R. 2006. Prevalence of extended spectrum β-lactamases among Escherichia coli and Klebsiella in Newzealand in 2006, Antibiotic Reference Laboratory. Communicable Disease Group; ESR Porirua.

Iroha IR, Adikwu MU, Esimone CO, Abinu I, Amadi ES. 2009. Exetended Spectrum Beta-Lactamase (ESBL) in Escherichia coli isolatedfrom a tertiary hospital in Enugu State, Nigeria. Pakistan Journal of Medical Sciences, 25(2), 279-282.

Lal P, Kapil A, Das B, Sood S. 2007. Occurenceof TEM and SHV genein extended spectrum beta lactamases (ESBLs) producing Klebsiellaspeciesisolated from a tertiary care hospital, Indian Journal of Medical Reseach, 125, 173-178.

Lin Y, Lu M, Hui-Ling, Tang H, Liu H, Chen C, Liu K, Lin C, Chiou C, Chiang M, Chen C, Yi-Chyi, Lai Y. 2011. Assessment of hypermucoviscosity as a virulence factor for experimental Klebsiella pneumoniae infections:comparative virulence analysis with hypermucoviscosity-negative strain, Bio Med Central Microbiology, 11, 50.

Lee CH, Su LH, Tang YF. 2006. Treatment of ESBL-producing Klebsiella pneumoniae bacteraemia with carbapenems or flomoxef: a retrospective study and laboratory analysis of the isolates. Journal of Antimicrobial Chemotherapy, 58, 1074–1077.

Livermore  DM,  Canton  R,  Gniadkowski  M. 2007. CTX-M: changing the face of ESBLs in Europe. Journal of Antimicrobial Chemotherapy,59, 165-74.

Livrelli V, Champs CD, Martino PD, Michaud AD, Forestier C, Joly B. 1996. Adhesive Properties and Antibiotic Resistance of Klebsiella, Enterobacter, and Serratia Clinical Isolates Involved in Nosocomial Infections, Journal of Clinical Microbiology, 34(8), 1963-1969.

Miller GH, Sabatelli FJ. 1997. The most frequent aminoglycoside resistance Mechanisms changes with time and geographic area: a reflection of aminoglycoside usage patterns? Aminoglycoside Resistance Study Groups, Clinical Infectious Diseases, 24(1), 46-62.

Mohammed A, Mohammed S, Asad UK. 2007. Etiology and antibiotic resistance patterns of community-acquired urinary tract infections in JNMC Hospital Aligarh, India. Annals of Clinical Microbiology and Antimicrobials, 6, 4.

Nicolle LE. 2008. Uncomplicated urinary tract infection in adults including uncomplicated pylo-nephritis. Urologic Clinics of North America, 35(1), 1–12.

Okesola AO, Fowotade A. 2012. Extended-spectrum beta-lactamase production among clinical isolates of Escherichia coli. Inernational Research Journal of Microbiology,3(4), 140-143.

Paterson DL. 2007. Recommendation for treatment of severe infections caused by Enterobacteriaceae producing extended-spectrum β-lactamases (ESBLs). Clinical Microbiology and Infection, 6, 460–463.

Perez F, Endimiani A, Hujer K, Bonomo RA. 2007. The continuing challenge of ESBLs. Current Opinion in Pharmacology, 7(5), 459-469.

Pitout JD, Gregson DB, Church DL. 2005. Community-wide outbreaks of clonally related CTX-M-14 β-lactamase-producing Escherichia coli strains in the Calgary Health Region. Journal of Clinical Microbiology, 43, 2844-2849.

Rodriguez-Bano J, Navarro MD, Romero L. 2004. Epidemiology and clinical features of infections caused by extended-spectrum β-lactamase-producing Escherichia coli in nonhospitalized patients. Journal of Clinical Microbiology, 42, 1089–1094.

Sabrina JM, Said A, Mabula K, Eligius F L, Samuel Y M. 2010. Antimicrobial resistance among producers and non-producers of extended spectrum beta-lactamases in urinary isolates at a tertiary Hospital in Tanzania.BMC Research Notes, 3, 348 doi:10.1186/1756-0500-3-348.

Samaha-Kfoury JN, Araj GF. 2003. Recent developments in β lactamases and extended spectrum β-lactamases, Bairut Medical Journal, 327(22), 1209-1213.

Sasirekha B, Manasa    R, Ramya P, Sneha R. 2010. Frequency and Antimicrobial Sensitivity Pattern Of Extended Spectrum β- Lactamases Producing Escherichia coli and Klebsiella pneumonia Isolated In A Tertiary Care Hospital, Al Ameen Journal of Medical science, 3(4), 265-271.

Sheryll L, Magalit MD, Maria I, Tarcela S, Gler MD, Thelma E, Tupasi MD. 2004. Increasing Antimicrobial Resistance Patterns of Community and Nosocomial Uropathogens in Makati Medical Center antibiotics, Philippines Journal of Microbiology and lnfectious Diseases, 33(4), 143-148.

Shobha KL, Gowrish RS, Sugandhi R, Sreeja CK. 2007. Prevalence of Extended Spectrum β-Lactamases in Urinary Isolates of Escherichia coli, Klebsiella and Citrobacter species and their Antimicrobial Susceptibility Pattern in tertiary care hospital, Indian journal for the Practicing Doctor, 3 (6), 01-02.

Steinke DT, Seaton RA, Phillips G, MacDonald TM, Davey PG. 2001. Prior trimethoprim use and trimethoprim-resistant urinary tract infection: A nested case-control study with multivariate analysis for other risk factors. Journal of Antimicrobial Chemotherapy, 47, 781-787.

Thomson KS. 2001. Controversies about extended-spectrum and AmpCβ-lactamases. Emerging Infectious Diseases, 7, 333–336.

Ullah F, Malik SA, Ahmed J. 2009. Antimicrobial susceptibility pattern and ESBL prevalence in Klebsiella pneumoniae from urinary tract infections in the North. West of Pakistan, African Journal of Microbiology, 3(11), 670- 680.

Yushau MM, Kumurya AS, Suleiman L. 2010. Prevalence of Extended spectrum β- lactamases among Enterobacteriaceae in Murtala Mohammed specialist hospital, Kano. Journal of Pure and Applied Sciences, 3(1), 169-172.

Submit Manuscript